Literature DB >> 9753304

Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor.

K A Elias1, M J Cronin, T A Stewart, R C Carlsen.   

Abstract

Mice (Ins.Dd1) with hypoinsulinemic diabetes were created by increased expression of syngeneic major histocompatibility complex (MHC) class I protein in pancreatic beta-cells. The diabetic state was characterized in these mice by high glucose concentrations and islet pathology. To determine whether a neuropathy would develop, motor and sensory conduction velocities (CV) were determined in the sciatic nerves of 2-, 4-, and 7-month-old control and diabetic littermate male mice. Recording bipolar electrodes were placed in the plantar muscles of the hind foot of anesthetized (ketamine/xylazine) mice. Bipolar stimulating electrodes were positioned near the sciatic nerve at the sciatic notch or near the tibial nerve at the ankle. Motor CV from alpha-motor fibers and sensory CV from proprioceptive Aalpha nerves were measured and expressed as meters per second (m/s). Group data are reported as mean +/- SE and compared by analysis of variance. The CVs from nondiabetic mice (controls) were not different across the three ages and averaged 41.3 +/- 1.7 m/s for motor and 38.7 +/- 1.7 m/s for sensory. The motor CVs from diabetic mice at 2 and 4 months were similar to controls. Sensory CVs were unchanged at 2 months but were lower at 4 months (18.9 +/- 2.4 m/s). Both sensory (23.9 +/- 2.1 m/s) and motor (18.9 +/- 1.8 m/s) CVs were significantly reduced at 7 months, which is indicative of a polyneuropathy. NGF has well-known trophic effects on sympathetic and small sensory neurons. To determine whether NGF could influence this neuropathy, 6-month-old control and diabetic mice were divided into the following groups: 1) control + vehicle, 2) diabetic + vehicle, and 3) diabetic + NGF (1 mg/kg, 3x week, s.c.). After 1 month of treatment, motor and sensory CVs were determined. In some mice, the branches of the sciatic nerve were exposed and in situ recordings from the sural nerve were performed to determine compound C-fiber CV, integral, and amplitude. Sensory CV, determined via Hoffmann's reflex (H-reflex) (A-fiber), was decreased in diabetic compared with control animals as expected (P < 0.05), and NGF did not alter this parameter. Continuing diabetes reduced the amplitude (0.9 +/- 0.2 vs. 3.2 +/- 0.7 mV x 10(-2); P < 0.05) and integral (6.9 +/- 1.9 mV/ms vs. 18.8 +/- 4.4 mV/ms; P < 0.05) of the C-fiber response versus control, suggesting fiber loss. NGF treatment normalized C-fiber amplitude (2.9 +/- 0.8 mV x 10(-2)) and integral (21.2 +/- 6.5 mV/ms) in animals with established diabetes, with no effect on blood glucose. The C-fiber CV was similar in all groups, indicating that the animals had some normally conducting small fiber sensory nerves. These studies characterized a motor and sensory polyneuropathy in transgenic diabetic mice and are the first to demonstrate directly that NGF treatment can protect or restore abnormal sensory C-fiber function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753304     DOI: 10.2337/diabetes.47.10.1637

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

1.  Neurologic Complications of Cancer Therapy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 2.  Mouse models of diabetic neuropathy.

Authors:  Phillipe D O'Brien; Stacey A Sakowski; Eva L Feldman
Journal:  ILAR J       Date:  2014

3.  Swedish Nerve Growth Factor Mutation (NGFR100W) Defines a Role for TrkA and p75NTR in Nociception.

Authors:  Kijung Sung; Luiz F Ferrari; Wanlin Yang; ChiHye Chung; Xiaobei Zhao; Yingli Gu; Suzhen Lin; Kai Zhang; Bianxiao Cui; Matthew L Pearn; Michael T Maloney; William C Mobley; Jon D Levine; Chengbiao Wu
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

4.  GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway.

Authors:  Mallappa Anitha; Chetan Gondha; Roy Sutliff; Alexander Parsadanian; Simon Mwangi; Shanthi V Sitaraman; Shanthi Srinivasan
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

5.  A brief review of in vitro models of diabetic neuropathy.

Authors:  Namita G Hattangady; Medha S Rajadhyaksha
Journal:  Int J Diabetes Dev Ctries       Date:  2009-10

Review 6.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

7.  The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers.

Authors:  Elisavet K Tiaka; Nikolaos Papanas; Anastassios C Manolakis; Efstratios Maltezos
Journal:  Int J Burns Trauma       Date:  2011-09-03

Review 8.  Criteria for creating and assessing mouse models of diabetic neuropathy.

Authors:  Kelli A Sullivan; Stephen I Lentz; John L Roberts; Eva L Feldman
Journal:  Curr Drug Targets       Date:  2008-01       Impact factor: 3.465

Review 9.  Mechanism of diabetic neuropathy: Where are we now and where to go?

Authors:  Soroku Yagihashi; Hiroki Mizukami; Kazuhiro Sugimoto
Journal:  J Diabetes Investig       Date:  2011-01-24       Impact factor: 4.232

10.  Therapeutic efficacy of bone marrow-derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes.

Authors:  Masaki Kondo; Hideki Kamiya; Tatsuhito Himeno; Keiko Naruse; Eitaro Nakashima; Atsuko Watarai; Taiga Shibata; Takahiro Tosaki; Jiro Kato; Tetsuji Okawa; Yoji Hamada; Ken-Ichi Isobe; Yutaka Oiso; Jiro Nakamura
Journal:  J Diabetes Investig       Date:  2014-09-11       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.